Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 12/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468321 | 0.80 | EGFR (0.54) | MEN1KMT2ATYK2JAK2JAK1 | |
| SCHEMBL23758885 | 0.78 | EGFR (0.53) | MEN1HPGDKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17796425 | 0.77 | TYK2 (0.59) | MEN1LMNAHPGDALOX15ALOX12 | |
| SCHEMBL29462402 | 0.75 | KMT2A (0.73) | MEN1LMNAHPGDALOX15ALOX12 | |
| SCHEMBL9706943 | 0.75 | KMT2A (0.73) | MEN1LMNAHPGDALOX15ALOX12 | |
| SCHEMBL134242 | 0.75 | KMT2A (0.73) | MEN1LMNAHPGDALOX15ALOX12 | |
| SCHEMBL16247965 | 0.74 | SLC22A12 (0.67) | — | |
| SCHEMBL23999925 | 0.74 | MAP4K4 (0.52) | HPGDSMN1; SMN2EGFR | |
| SCHEMBL17730045 | 0.74 | IDO1 (0.71) | — | |
| SCHEMBL23130441 | 0.74 | IDO1 (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998296-B1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-2998296-B1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2018-03-14 | — | — | EP | disclosed |
| US-9637484-B2 | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-02 | — | — | US | disclosed |
| US-9637484-B2 | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-05-02 | — | — | US | disclosed |
| US-20160108035-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co., Lt.d (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160108035-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co., Lt.d (CN) | 2016-04-21 | — | — | US | disclosed |
| EP-2998296-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2016-03-23 | — | — | EP | disclosed |
| EP-2998296-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014183555-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | 上海恒瑞医药有限公司 (CN) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108035-A1 | CYCLOALKYL ACID DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION THEREOF | UGP2, MPST, KYAT1 | MEN1 4145/4885LMNA 3806/4885HPGD 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.